(firstQuint)Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD).

 Behavioral disturbances are a major cause of morbidity in frontotemporal dementia (FTD), yet little is known about the effectiveness of medications to treat these disturbances.

 Preliminary data suggests that the dopaminergic agent amantadine may reduce these disturbances.

 This 6-week, prospective, randomized, placebo-controlled trial will compare amantadine to placebo to assess its effectiveness in reducing behavioral symptoms.

.

 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)@highlight

The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.

